Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.4 3.7

Overview

Share price change

24h

Current

Min

1.33

Max

1.41

Key metrics

By Trading Economics

Income

32M

-8.3M

Sales

-7.5M

37M

EPS

-0.12

Profit margin

-22.258

Employees

485

EBITDA

33M

-5.8M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+75% upside

Dividends

By Acuity

Next Earnings

5 sie 2026

Market Stats

By TradingEconomics

Market Cap

-59M

422M

Previous open

-2.3

Previous close

1.4

News Sentiment

By Acuity

50%

50%

145 / 340 Ranking in Healthcare

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lip 2026, 13:01 UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

20 lip 2026, 23:01 UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

75% upside

12 Months Forecast

Average 2.38 USD  75%

High 3 USD

Low 1.5 USD

Based on 4 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

2

Buy

1

Hold

1

Sell

Sentiment

By Acuity

145 / 340 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat